Mark Budde - How to speed up wet-lab biology

Scientific progress is hindered by the time and cost required to convert hypotheses into actionable data. Mark Budde, CEO of Plasmidsaurus, addresses this bottleneck by providing high-speed, affordable sequencing services that automate complex laboratory workflows. By reducing the cost of whole plasmid sequencing to $15 and streamlining RNA-Seq analysis, the company enables researchers to focus on biological discovery rather than manual labor. Success stems from a relentless focus on logistics, custom automation, and a user-centric interface that removes technical burdens from scientists. While the company possesses vast amounts of proprietary data, it maintains a strict policy against selling customer information to AI labs, instead positioning itself as a vital infrastructure provider. Future growth targets additional biological "digitization" opportunities, such as mass spectrometry, to further accelerate the pace of scientific research and therapeutic development.